

“Thanks to all of you who have **cared**, loved,
and used your minds **so brilliantly** to help us.
Without you, we wouldn't stand a chance.”

— **Belinda Miller**

WE ARE HONORED THAT YOU CHOSE TO SUPPORT US.

FSH muscular dystrophy, a debilitating disease affecting nearly a million men, women, and children worldwide, has long lacked any treatment, but because of you, our families can look forward to having a therapy by the year 2025, if not sooner.

BECAUSE OF YOU, thousands of families can get support from local chapter leaders and become activists in their communities.

YOU HAVE CATALYZED BREAKTHROUGH RESEARCH

on stem cells, CRISPR, new treatment strategies, and more than \$100 million of private investment in FSHD therapies.

THANKS TO YOU, we are launching the FSHD Therapeutic Accelerator Project to remove barriers to FDA approval of promising treatments.

Together, we have journeyed incredible distances. With your continued support, we will reach our goal!

— **MARK STONE**

President & CEO



FSH Society

450 Bedford Street
Lexington, MA 02420 USA

NON-PROFIT
ORGANIZATION
U.S. Postage
PAID
PERMIT NO. 1036
DULUTH, MN

Education



PARTICIPANTS
1,900

- 1 FSHD CONNECT CONFERENCE
- 3 FAMILY DAY CONFERENCES
- 4 WEBINARS

YOUTUBE
VIEWS
27,000



Engagement



NEW
MEMBERS **2,300**

VOLUNTEERS **813**

SUPPORTERS **3,281**

CHAPTERS
LAUNCHED **17**

MEMBERS
SERVED **4,700**

WALK & ROLL
FUNDRAISERS **5**

NUMBER OF
WALKERS **542**

FUNDS RAISED **\$239,000**



Results that matter

Our vision is a world free of the suffering caused by FSH muscular dystrophy (FSHD). In 2018, we saw remarkable progress toward treatments and greatly expanded our ability to serve our members. Here is what we have accomplished, thanks to your dedicated support.

www.fshsociety.org

Financials


Cash basis

REVENUE RAISED

\$2.8 million



- Research
- Patient Advocacy and Education
- Community Development
- Administrative



Accelerating Research

RESEARCH INVESTMENT

\$1.8 million

INTERNATIONAL
RESEARCH CONGRESS
ATTENDEES

135

CLINICAL TRIAL RESEARCH
NETWORK SITES

11



2018 NIH FUNDING
OF FSHD RESEARCH

\$17.9 million

THERAPIES IN
DEVELOPMENT

12

BIOTECH & PHARMA
PARTNERS

8